Key result
Atrial natriuretic peptide suppresses angiotensin II-induced TF and PAI-1 expression in endothelial cells.
Why the study?
The role of atrial natriuretic peptide on blood coagulation and fibrinolysis mediated by vascular endothelial cells was previously unreported.
The pharmacological characteristics of atrial natriuretic peptide (ANP), such as natriuresis, vasodilation, or suppression of smooth muscle cell proliferation, are well investigated. However, this is the first study to report its role on blood coagulation and fibrinolysis mediated by vascular endothelial cells. In this study, the effects of ANP on the enhanced expression of tissue factor (TF) and plasminogen activator inhibitor 1 (PAI-1) by angiotensin II (Ang II) in cultured rat aortic endothelial cells (RAECs) were examined. The expressions of TF and PAI-1 mRNA were detected by northern blotting methods. The activities of TF on the surface of RAECs and PAI-1 in the culture media were measured by chromogenic assay. ANP suppressed mRNA expressions of TF and PAI-1 induced by Ang II in a concentration-dependent manner. This suppression was accompanied by the decreased activities of TF and PAI-1.
No takes yet. Share an insight, caveat, or question.
A 1998 study studied this question. Atrial natriuretic peptide (ANP) vs. Angiotensin II alone was evaluated on Expression and activity of tissue factor (TF) and plasminogen activator inhibitor 1 (PAI-1). Atrial natriuretic peptide suppressed the mRNA expression and activity of tissue factor and plasminogen activator inhibitor 1 induced by angiotensin II in cultured rat aortic endothelial cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: